Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure

Environment International

Volumn 56, Issue , 2013, Pages 42-47

  Lee, Pei Chen ^a,b   Rhodes, Shannon L ^a   Sinsheimer, Janet S ^c   Bronstein, Jeff ^c   Ritz, Beate ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Organophosphate pesticide; Paraoxonase 1; Parkinson's disease

Indexed keywords

GEOGRAPHIC INFORMATION SYSTEMS; HOUSING; PESTICIDES;

AGRICULTURAL PESTICIDES; GEOGRAPHIC INFORMATION; ORGANOPHOSPHATE PESTICIDES; PARAOXONASE 1; PARKINSON'S DISEASE; POPULATION CONTROL; PROMOTER REGION; SAMPLE SIZES;

NEURODEGENERATIVE DISEASES;

ARGININE; ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; CYSTEINE; DIMPYLATE; GLUTAMINE; LEUCINE; METHIONINE; PARATHION; THREONINE;

CHLORPYRIFOS; DIAZINON; DISEASE; ENZYME; GENOTYPE; ORGANOPHOSPHATE; PESTICIDE; POLYMORPHISM;

AGED; ARTICLE; ARYLDIALKYLPHOSPHATASE 1 GENE; CAUCASIAN; CONTROLLED STUDY; EXON; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IDIOPATHIC DISEASE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RESIDENTIAL AREA; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; WORKPLACE;

CALIFORNIA; UNITED STATES;

EID: 84876442377     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2013.03.004     Document Type: Article

References (40)

1. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
2. Bekris L.M., Mata I.F., Zabetian C.P. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010, 23:228-242.
3. Belin A.C., Ran C., Anvret A., Paddock S., Westerlund M., Hakansson A., et al. Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neurosci Lett 2012, 522:30-35.
4. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., Furlong C.E. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001, 68:1428-1436.
5. Paraoxonase (PON1) in health and disease: basic and clinical aspects 2002, Kluwer Academic Publishers, Norwell, MA. L. Costa, C. Furlong (Eds.).
6. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003, 54:371-392.
7. Costa L.G., Richter R.J., Li W.F., Cole T., Guizzetti M., Furlong C.E. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 2003, 8:1-12.
8. Costa L.G., Cole T.B., Vitalone A., Furlong C.E. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005, 352:37-47.
9. Costello S., Cockburn M., Bronstein J., Zhang X., Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009, 169:919-926.
10. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996, 14:334-336.
11. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
12. Freire C., Koifman S. Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 2012.
13. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997, 99:62-66.
14. Goldberg D.W., Wilson J.P., Knoblock C.A., Ritz B., Cockburn M.G. An effective and efficient approach for manually improving geocoded data. Int J Health Geogr 2008, 7:60.
15. Hancock D.B., Martin E.R., Mayhew G.M., Stajich J.M., Jewett R., Stacy M.A., et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 2008, 8:6.
16. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
17. Jacob E.L., Gatto N.M., Thompson A., Bordelon Y., Ritz B. Occurrence of depression and anxiety prior to Parkinson's disease. Parkinsonism Relat Disord 2010, 16:576-581.
18. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 2007, 165:364-374.
19. Kang G.A., Bronstein J.M., Masterman D.L., Redelings M., Crum J.A., Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005, 20:1133-1142.
20. Langston J.W., Widner H., Goetz C.G., Brooks D., Fahn S., Freeman T., et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992, 7:2-13.
21. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
22. Liu Y.L., Yang J., Zheng J., Liu D.W., Liu T., Wang J.M., et al. Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: a HuGE review and meta-analysis. Gene 2012, 501:188-192.
23. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
24. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139:341-349.
25. Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010, 21:87-94.
26. Muangpaisan W., Hori H., Brayne C. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemiol 2009, 19:281-293.
27. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A.G. Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. Am J Hum Genet 1983, 35:393-408.
28. O'Leary K.A., Edwards R.J., Town M.M., Boobis A.R. Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet Genomics 2005, 15:51-60.
29. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
30. Richter R.J., Jarvik G.P., Furlong C.E. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009, 235:1-9.
31. Ritz B., Costello S. Geographic model and biomarker-derived measures of pesticide exposure and Parkinson's disease. Ann N Y Acad Sci 2006, 1076:378-387.
32. Ritz B., Rhodes S.L., Bordelon Y., Bronstein J. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One 2012, 7:e36199.
33. Rull R.P., Ritz B. Historical pesticide exposure in California using pesticide use reports and land-use surveys: an assessment of misclassification error and bias. Environ Health Perspect 2003, 111:1582-1589.
34. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996, 46:1275-1284.
35. Taylor M.C., Le Couteur D.G., Mellick G.D., Board P.G. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 2000, 107:979-983.
36. van der Mark M., Brouwer M., Kromhout H., Nijssen P., Huss A., Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 2012, 120:340-347.
37. von Campenhausen S., Bornschein B., Wick R., Botzel K., Sampaio C., Poewe W., et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005, 15:473-490.
38. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891.
39. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26(Suppl. 1):S1-S58.
40. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J Hum Genet 2004, 49:474-481.